Gideon E. Bollag
Impact in
- Oncology top 0.2%
- Colorectal Cancer Treatments and Studies
- Cancer-related Molecular Pathways
- Molecular Biology top 0.2%
- Melanoma and MAPK Pathways
- Protein Kinase Regulation and GTPase Signaling
- PI3K/AKT/mTOR signaling in cancer
Papers in
-
- Melanoma and MAPK Pathways 40
- Protein Kinase Regulation and GTPase Signaling 24
- PI3K/AKT/mTOR signaling in cancer 14
- Protein Tyrosine Phosphatases 12
- Oncology 35
- Co-authors
- KEVIN M. SHANNON (19 shared papers)Frank P. McCormick (13 shared papers)Suzanne Schubbert (6 shared papers)Chao Zhang (9 shared papers)Neal X. Rosen (3 shared papers)Poulikos I. Poulikakos (4 shared papers)Kevan M. Shokat (2 shared papers)Brian L. West (14 shared papers)
- Journals
- Proceedings of the National Academy of Sciences (11 papers)Cancer Research (8 papers)Methods in enzymology on CD-ROM/Methods in enzymology (7 papers)Blood (7 papers)Nature (6 papers)
- Partner nations
- United StatesGermanyCanada
In The Last Decade
Gideon E. Bollag
134 papers receiving 24.3k citations
Gideon E. Bollag's Hit Papers
Peers
Comparison fields: 5 of 151
- Oncology 7.4k
- Molecular Biology 15.6k
- Pathology and Forensic Medicine 2.5k
- Cancer Research 2.0k
- Immunology 2.6k
Countries citing papers authored by Gideon E. Bollag
This map shows the geographic impact of Gideon E. Bollag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gideon E. Bollag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gideon E. Bollag more than expected).
Fields of papers citing papers by Gideon E. Bollag
This network shows the impact of papers produced by Gideon E. Bollag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gideon E. Bollag. The network helps show where Gideon E. Bollag may publish in the future.
Co-authors
The 25 scholars most cited alongside Gideon E. Bollag, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 135 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis Hit paper breakdown → | 2004 | 3503 |
| 2 | RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Hit paper breakdown → | 2010 | 1526 |
| 3 | Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Hit paper breakdown → | 2010 | 1518 |
| 4 | Hyperactive Ras in developmental disorders and cancer Hit paper breakdown → | 2007 | 1284 |
| 5 | Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Hit paper breakdown → | 2008 | 1128 |
| 6 | RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors Hit paper breakdown → | 2012 | 889 |
| 7 | The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21 Hit paper breakdown → | 1990 | 856 |
| 8 | 1998 | 689 | |
| 9 | Vemurafenib: the first drug approved for BRAF-mutant cancer Hit paper breakdown → | 2012 | 671 |
| 10 | Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model Hit paper breakdown → | 2019 | 636 |
| 11 | 2006 | 595 | |
| 12 | 1996 | 507 | |
| 13 | 2013 | 499 | |
| 14 | Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor Hit paper breakdown → | 2015 | 467 |
| 15 | 2010 | 386 | |
| 16 | 2004 | 372 | |
| 17 | 1992 | 361 | |
| 18 | 2001 | 351 | |
| 19 | 2010 | 345 | |
| 20 | 1995 | 335 |
About Gideon E. Bollag
Gideon E. Bollag is a scholar working on Molecular Biology, Oncology, Neurology, Immunology and Cell Biology, having authored 135 papers that have together received 25.2k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (40 papers), Protein Kinase Regulation and GTPase Signaling (24 papers), Cancer Mechanisms and Therapy (14 papers), PI3K/AKT/mTOR signaling in cancer (14 papers), Neurofibromatosis and Schwannoma Cases (13 papers), Neuroblastoma Research and Treatments (12 papers), Computational Drug Discovery Methods (12 papers) and Protein Tyrosine Phosphatases (12 papers). The work is most often cited by research in Oncology (7.4k citations), Molecular Biology (15.6k citations), Pathology and Forensic Medicine (2.5k citations), Cancer Research (2.0k citations) and Immunology (2.6k citations). Gideon E. Bollag has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include KEVIN M. SHANNON, Frank P. McCormick, Suzanne Schubbert, Chao Zhang, Neal X. Rosen, Poulikos I. Poulikakos, Kevan M. Shokat, Brian L. West, George A. Martin and Prabha N. Ibrahim. Their work appears in journals such as Proceedings of the National Academy of Sciences, Cancer Research, Methods in enzymology on CD-ROM/Methods in enzymology, Blood and Nature.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.